Alessia Argirò, Mattia Zampieri, Alberto Marchi, Annamaria Del Franco, Eszter Dalma Pàlinkàs, Giulia Biagioni, Chiara Chiti, Carlotta Mazzoni, Alessandra Fornaro, Mattia Targetti, Francesco Cappelli, Iacopo Olivotto
{"title":"[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy].","authors":"Alessia Argirò, Mattia Zampieri, Alberto Marchi, Annamaria Del Franco, Eszter Dalma Pàlinkàs, Giulia Biagioni, Chiara Chiti, Carlotta Mazzoni, Alessandra Fornaro, Mattia Targetti, Francesco Cappelli, Iacopo Olivotto","doi":"10.1714/4100.40979","DOIUrl":null,"url":null,"abstract":"<p><p>Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.</p>","PeriodicalId":12510,"journal":{"name":"Giornale italiano di cardiologia","volume":"24 10","pages":"792-799"},"PeriodicalIF":0.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di cardiologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1714/4100.40979","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Hypertrophic cardiomyopathy is the most common genetic cardiomyopathy. Main complications include the development of arrhythmias and heart failure, and the latter may be triggered by left ventricular outflow tract obstruction. The treatment of left ventricular outflow tract obstruction includes pharmacological therapies (beta-blockers, calcium channel blockers, disopyramide) and septal reduction therapies (alcohol septal ablation, surgical myectomy). Myosin inhibitors represent a new therapeutic opportunity and in recent clinical trials proved effective in symptom relief, improvement of functional capacity and quality of life in patients with obstructive hypertrophic cardiomyopathy. In this narrative review we will summarize the available and under development therapeutic approaches for hypertrophic cardiomyopathy.